Latest Outcomes in Adult Patients With Ph+ ALL Using TKIs With Modified USC RegimenBySamvel Nazaretyan, PharmD Candidate,Vincent Mendiola, MD,George Yaghmour, MD,Amir Ali, PharmD, BCOPApril 18th 2023Substantial strides have been made in the management of Ph+ ALL.
FLT3 Inhibitors Sustain Prolonged Remission in AML Post HSCTBySamvel Nazaretyan, PharmD Candidate,Amir Ali, PharmD, BCOP,George Yaghmour, MDJanuary 17th 2023A retrospective analysis presents unique results for AML treatment.